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Abstract
Background: The IL23/Th17 pathway is essential for the onset of inflammatory bowel disease (IBD), yet the specific
mechanism by which this pathway initiates the disease remains unknown. In this study, we identify the
mechanisms that mediate cross-talk between the IL23 pathway and the intestinal barrier in IBD.
Results: The downstream targets of the IL23 pathway were identified by RNA array profiling and confirmed by
immunohistochemical staining. The role of miRNAs that interact with IL23 was explored in mice with TNBS-induced
colitis. Claudin-8 (CLDN8), a multigene family protein that constitutes the backbone of tight junctions, was
identified as a novel target of IL23 in IBD. CLDN8 was significantly downregulated in IBD patients with inflamed
colonic mucosa, and in trinitrobenzene sulphonic acid (TNBS) induced colitis in mice. Therapeutic treatment of
colitis in mice using an IL23 antibody restored CLDN8 abundance, in parallel with recovery from colitis. In addition,
we identify miR-223 as a novel mediator of the crosstalk between the IL23 signal pathway and CLDN8 in the
development of IBD. MiR-223 was upregulated in IBD, and its activity was regulated through the IL23 pathway.
Antagomir inhibition of miR-223 reactivated CLDN8 and improved a number of signs associated with TNBS-induced
colitis in mice.
Conclusions: Our study characterizes a new mechanistic pathway in IBD, in which miR-223 interacts with the IL23
pathway by targeting CLDN8. Strategies designed to disrupt this interaction may provide novel therapeutic agents
for the management of IBD.
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Background
Inflammatory bowel disease (IBD) comprises two distinct
phenotypes: ulcerative colitis (UC) and Crohn’s disease
(CD), each of which has unique clinical manifestations
while sharing many genetic and mechanistic features
[1, 2]. In the past decade, the incidence of IBD in Asia has
increased dramatically. Our recent population-based study
showed that Guangzhou and Hong Kong are among the
top three cities in Asia with the highest incidence of IBD
at 3.44 and 3.06 per 100,000, respectively [3]. Although
the exact pathophysiology of IBD is not fully understood,
the etiology of this disease is known to be multifactorially
driven by a number of genetic and environmental factors,
including loss of regulation of the host’s innate immune
response and defects in mucosal barrier function [4].
The intestinal epithelial barrier is crucial for maintain-
ing the intestinal homoeostasis because of its location
between the luminal bacteria and the host’s innate im-
mune system. This epithelial barrier represents the first
exposure to various external environmental factors,
which can trigger the onset of various diseases, including
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IBD [5]. Tight junctions (TJs) are the main components
of the intestinal epithelial barrier, and they function pri-
marily in controlling cellular polarity and adhesion [6].
The components of the tight junction include Occludin,
Tricellulin [7], the junctional adhesion molecule (JAM)
proteins [8], and the large Claudin family. The Claudins,
consisting of 24–27 members in mammalian genomes,
are the major determinant of electrolyte permeability
through the paracellular pathway, and are regarded as
the backbone of the intestinal barrier [9]. Claudins have
been reported to be dysregulated in IBD patients.
Recent studies have found that the IL23/Th17 axis is
involved in the regulation of IBD [10, 11]. Inhibition of
the pathway by anti-IL23P19 monoclonal antibody at-
tenuated Trinitrobenzene sulfonic acid (TNBS)-induced
Crohn’s disease in rats [12]. Although both the dysfunc-
tion of intestinal barrier properties and the IL23/Th17
pathway are key contributors to the onset of IBD, it is
still not clear whether there exists a link between these
two factors in mediating the chronic inflammation of
IBD.
MiRNAs are small non-coding RNAs that regulate
gene expression by base pairing with target mRNAs at
the 3’-untranslated region, leading to mRNA cleavage
and translational repression [13, 14]. It has been sug-
gested that miRNAs regulate tens or hundreds of targets
[15], and a number of biological processes are regulated
by miRNAs, including cell proliferation, cell death, stress
resistance, and differentiation of intestinal epithelial cells
[16, 17]. It has also been reported that the expression of
miRNAs is abnormal in IBD patients, suggesting that
the altered expression of miRNAs may be involved in
pathogenesis of IBD [18, 19]. However, the role of miR-
NAs in the IL23 pathway has not been explored.
Previous studies found that cytokines, including TNF-
α, might induce or inhibit the expression of miRNAs
[20, 21]. Therefore, we hypothesized that the IL23 path-
way might interact with miRNAs to cause dysfunction of
the intestinal epithelial barrier. In this study, we sought
to identify the downstream targets of the IL23 pathway
in the development of IBD, including those miRNAs that
mediate the cross-talk between the IL23/Th17 axis and
the intestinal epithelial barrier.
Results
The role of the IL23 pathway in TNBS-induced colitis
The IL23/Th17 pathway is critical to the onset of IBD.
To delineate the mechanisms underlying the role of
IL23 in IBD, we established a colitis model in BALB/c
mice using TNBS, and treated these mice with anti-
IL23P19 mAb. The animals with colitis that were treated
with anti-IL23P19 (TNBS + P19) experienced a signifi-
cant recovery in body weight compared to the isotype
control group (TNBS + ISO) (Fig. 1a). In addition, the
anti-IL23P19 treatment improved many cardinal signs of
colitis in the animals, including the area of ulceration, a
depletion of mucin-producing goblet and epithelial cells,
a thickening of the muscular layer, degree of leukocyte
and PMN infiltration, as well as histological scores
(Fig. 1b-d).
The role of the IL23 pathway in the pathogenesis of
IBD was also evaluated by two additional assays. Intes-
tinal permeability was examined using the FITC-labeled
dextran assay. We found that the anti-IL23P19 group
showed a significantly greater decrease in intestinal per-
meability to FITC-dextran when compared with the iso-
type control group (P <0.01) (Fig. 1e). Similarly, the
colonic myeloperoxidase (MPO) activity, a biochemical
assay for acute intestinal inflammation, was significantly
alleviated by the anti-IL23P19 treatment (Fig. 1f). Together,
these data confirm that targeting this over-reactive pro-
inflammatory pathway is an effective therapeutic strategy
against IBD as previously reported [22–24].
Identification of CLDN8 as a novel target gene in IBD
Using microarray analyses in IBD tissues, Fang et al. re-
ported that hundreds of genes are altered in IBD tissues,
including the CXC chemokine family, SLC16A9,
SLC17A4, SLC23A3, and SLC3A1 [25]. To identify mo-
lecular targets in the IL23 pathway, we used an RNA
microarray chip to screen genes that are differentially
expressed between IBD and healthy controls. In this
study, we found that there were 353 genes that showed
greater than four-fold differential expression (285 upreg-
ulated and 68 downregulated) (Additional files 1 and 2:
Tables S1 and S2). Among them, claudin-8 (CLDN8), a
member of the claudin family proteins that constitute
the backbone of the intestinal barrier, was highly
expressed in normal tissues, but was downregulated in
IBD tissues (Additional file 3: Figure S1A). In clinically
collected tissue samples, we confirmed that CLDN8 was
significantly downregulated in patients with CD and UC
as compared with that in control patients (Fig. 2a, quan-
titative PCR; Additional file 3: Figure S1B, western blot).
Consistent with these findings, immunohistochemical
(IHC) staining also demonstrated that CLDN8 was sig-
nificantly reduced in IBD colonic mucosa (Fig. 2b, inte-
grated optical density (IOD), P <0.01).
Similarly, in the colitis animal model we observed the
downregulation of CLDN8 in TNBS-induced colitis tis-
sues. Interestingly, treatment with anti-IL23P19 increased
CLDN8 2.8-fold (Fig. 2c, quantitative PCR, P = 0.028;
Additional file 3: Figure S1C, western blot). Upregulation
of CLDN8 by anti-IL23P19 was also confirmed in mice
with colitis as compared with the isotype controls using
IHC staining (Fig. 2d). The Claudin family proteins are re-
quired for proper functioning of the intestinal barrier.
Dysfunction of the intestinal barrier contributes to the
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onset of IBD. Our data thus identify CLDN8 as a novel
gene target both in IBD patients and in the anti-IL23P19-
treated colitis animal model.
CLDN8 is required for the maintenance of junction
tightness of colonic cells
Measurement of transepithelial electrical resistance
(TEER) is considered to be a good indication of the
tightness of junctions between colonic cells. We investi-
gated the role of CLDN8 by knocking down CLDN8
using siRNA or overexpressing it by ectopic expression
of CLDN8 in Caco-2 cells (Fig. 3a-d). As compared with
the control group (si-control), knockdown of CLDN8
significantly reduced the TEER. In contrast, ectopic
expression of CLDN8 significantly enhanced the tight
junction of epithelial cells (Fig. 3e). Thus, the newly
identified CLDN8 is required for maintaining normal in-
testinal barrier properties.
CLDN8 is a novel downstream component of the IL23
pathway
We examined the role of IL23 in the regulation of
CLDN8 in two human colonic epithelial cell lines. After
treating NCM460 cells with IL23 for 72 h, transcrip-
tional expression levels of CLDN8 in intestinal epithelial
cells were assessed by Q-PCR. CLDN8 was downregu-
lated by 84 % in the IL23-treated group (P = 0.019).

























1       2      3       4       5       6       7      8 
A Body weight

















































Fig. 1 The pathological role of the IL23/Th17 pathway in TNBS-induced colitis. a Recovery of body weight in mice with TNBS-induced colitis by
anti-IL23P19. Control: colitis mice treated with ethanol; TNBS + P19: TNBS-induced colitis mice treated with an IL23 antibody; TNBS + ISO: TNBS-induced
colitis mice treated with an isotype control; *P <0.05, **P <0.01, ***P <0.001 for comparison between the TNBS + ISO and the Ethanol Control; #P <0.05
for the statistical significance between the TNBS + P19 treatment group and the TNBS + ISO control group. b Representative images of the colon
in treated mice with colitis. c Representative cross-sections of the transverse colon. Magnification of the images is 200-fold. d Anti-IL23P19 therapy
reduces the histological score. *P <0.05 as compared with the TNBS + ISO control group. e Serum FITC-dextran was quantified as a measure of
intestinal permeability. **P <0.01 as compared with the TNBS + ISO control group. f Effects on MPO activity measurement by Anti-IL23P19. *P <0.05 as
compared with the TNBS + ISO control group
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reduced the reduction of CLDN8 (P <0.05) (Fig. 4a, b).
Similar results were also observed in Caco-2 cells
(Fig. 4c, d).
We further examined the impact of IL23 on intestinal
barrier properties by measuring transepithelial electrical
resistance (TEER). Treatment of Caco-2 cells with IL23
resulted in a decrease in TEER by 76.4 % (Fig. 4e). How-
ever, co-treatment with anti-IL23P19 significantly atten-
uated the damage of this intestinal barrier property.
Together, these results suggest that the IL23 pathway
affects the intestinal barrier property.
MiR-223 targets CLDN8 in the IL23 pathway
We then sought to delineate the mechanism by which
IL23 targets CLDN8 in the dysfunctional intestinal bar-
rier property in IBD. Using microRNA prediction algo-
rithms (www.microRNA.org), we identified miR-223 as a
putative candidate microRNA that targets the 3’-UTR of
CLDN8 (Fig. 5a, left panel).
To test the role of miR-223 in regulating the 3’-UTR
of CLDN8, we constructed a plasmid encoding a firefly
luciferase transcript with either the wild-type or a mu-
tant 3’-UTR of CLDN8. We found that the miR-223
mimic decreased the expression of the transcript con-
taining the wild-type 3’-UTR of CLDN8, while the miR-
223 inhibitor increased the expression (Fig. 5a, right
panel). However, miR-223 did not cause significant
changes in the transcript containing the mutant 3’-UTR
of CLDN8. These data demonstrate a specific inhibitory
effect of miR-223 on the 3’-UTR of CLDN8.
We then examined the regulatory effect of miR-223 on
endogenous CLDN8 by transfecting vectors containing
miR-223 mimic, inhibitor, or controls into Caco-2,
NCM460, and SW480 cells (Additional file 4: Figure S2).
MiR-223 mimics inhibited CLDN8 expression at both
the mRNA and protein levels (Fig. 5b, left panel: quanti-
tative PCR; right panel: western blot). On the other
hand, when cells were transfected with miR-223 inhibi-
tor, the mRNA transcript and protein level of CLDN8
were elevated compared with control-transfected cells
(Fig. 5c, left panel: quantitative PCR; right panel: western
blot). These data indicate that endogenous CLDN8 is
negatively regulated by miR-223 in colonic epithelial
cells.
MiR-223 is negatively correlated with CLDN8 in UC and
CD patients
Considering the role of miR-223 in targeting CLDN8,
we determined whether they were differentially
expressed in colonic mucosa of IBD patients. A total
of 50 CD and 50 UC colonic mucosa and 50 normal
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Fig. 2 Identification of CLDN8 as a novel target controlled by the IL23 pathway in IBD patients. a Quantitative PCR of CLDN8 in colonic inflamed
mucosa of IBD patients. CD: Crohn’s disease (n = 50); UC: ulcerative colitis (n = 50); NT: normal subjects (n = 50). ***P <0.001 as compared with
normal controls. b Representative immunostaining of CLDN8 in IBD-inflamed tissues and normal intestinal. Magnification of the images is 200-fold.
IOD: Integrated optical densities of CLDN8 in colonic inflamed mucosa of IBD patients. **P <0.01 as compared with normal controls. c Anti-IL23P19
treatment reverses the downregulation of CLDN8 in TNBS-induced colitis tissues. *P <0.05, ***P <0.001 as compared with the controls. d Representative
immunostaining of CLDN8
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patients, the expression of miR-223 was 4.87-fold
higher than that in the normal subjects (P <0.001,
Fig. 5d). Similarly, in the colonic mucosa of UC pa-
tients, miR-223 was 2.9-fold higher than that seen in
normal colonic mucosa (P <0.001).
We then use a FISH assay to compare the expres-
sion pattern of mirR-223 and CLDN8 in colonic mu-
cosa. We found that miR-223 was upregulated, while
CLDN8 was downregulated in colonic mucosa from
IBD patients. There was a clear correlation between
miR-223 and CLDN8 in colonic tissues of the IBD pa-
tients (Fig. 5e).
The TEER assay was then used to verify the effects of
miR-223 mimics and inhibitors on the tightness of junc-
tions between colonic cells. Incubation of the monolayer
colonic cells with miR-223 mimics resulted in a decrease
in TEER by 64 % compared to the control group. In con-
trast, miR-223 inhibitors increased the TEER by 35.4 %
(Fig. 5f ). These results indicate that miR-223 affects the
tightness of junctions between colonic cells.
CLDN8

























































Fig. 3 CLDN8 regulates TEER in Caco-2 cells. a, b: Knockdown of CLDN8 by siRNA in Caco-2 cells as quantitated by qPCR (a) and western blot (b).
c, d Ectopic expression of CLDN8 in Caco-2 cells as quantitated by qPCR (c) and western blot (d). e CLDN8 regulates the TEER in Caco-2 cells.
*P <0.05, **P <0.01 as compared with the control
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Therapeutic treatment of TNBS-induced colitis mice
To further confirm the role of miR-223 in IBD, we tested
the potential of miR-223 antagomir treatment in mice
with TNBS-induced colitis. As seen in Fig. 6a, body
weights for the antagomir-control (TNBS + Anti-CTL)
group were significantly decreased compared to the con-
trol group (only treated with ethanol). However, the
antagmir223 treatment resulted in significant recovery in
body weight compared to the antagomir-control group.
Animals with TNBS-induced colitis showed large areas
of ulceration, severe depletions of mucin-producing gob-
let and epithelial cells, thickening of the muscular layer,
and high levels of leukocyte and polymorphonuclear
(PMN) infiltration. Administration of mirVana® miRNA
inhibitors improved the above-mentioned signs and the
histological scores (Fig. 6b, Additional file 5: Figure S3B
and S3C).
To define the role of mirVana® miRNA inhibitors on
mucosal barrier, intestinal permeability was examined in
the mice. Mice treated with antagmir223 exhibited a sig-
nificantly greater decrease in intestinal permeability to
FITC-dextran as compared to the antagomir-control
group (P <0.01) (Fig. 6c). Similarly, the antagomir-223
therapy reduced acute intestinal inflammation as
measured by colonic myeloperoxidase (MPO) activity
(Additional file 5: Figure S3D).
By inhibiting miR-223, the mirVana® miRNA inhibitor
reactivated CLDN8 in colitis tissues (Fig. 6d-f, P <0.01),
in parallel with the recovery in loss of body weight, and
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Fig. 4 IL23 downregulates CLDN8 in Caco-2 and NCM460 cells. a, b IL23 downregulates CLDN8 in NCM460 cells as quantitated by qPCR (a) and
western blot (b). c, d IL23 downregulates CLDN8 in Caco-2 cells as quantitated by qPCR (c) and western blot (d). e IL23 decreases TEER. NC: cells
treated with PBS. *P <0.05, **P <0.01, ***P <0.001
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score and MPO activity, and the preservation of the in-
tegrity of the intestinal epithelial barrier.
Crosstalk between IL23, MiR-223, and CLDN8 in the
development of IBD
Given the importance of miR-223 in IBD, we further ex-
amined if the microRNA was also controlled by the IL23
pathway. Two colonic epithelial cell lines (NCM640 and
Caco-2) were treated with IL23 for 72 h. The expression
of miR-223 and CLDN8 were assessed by Q-PCR. Com-
pared to the control, the expression miR-223 was in-
creased by 3.6-fold in NCM460 cells (P <0.05, Fig. 7a).
However, co-treatment with anti-IL23P19 attenuated the
activation of miR-223, compared with the isotype-control
(P <0.05). Similar data were also observed in Caco-2 cells
(Fig. 7a).
We then examined the regulation of miR-223 by
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Fig. 5 Identification of miR223 in targeting CLDN8 in colonic epithelial cells. a Regulation of the CLDN8 3’-UTR reporter by miR-223 mimics or inhibitors.
Left panel: Targeting sequences of wild-type (wt) and mutant (mut) 3’-UTR of the human CLDN8. The mutated sequences are marked in red. Right
panel: The gene activity was quantitated by luciferase assay in 293T cells. WT: wild type 3’-UTR; Mut: mutant 3’-UTR. b MiR-223 mimics downregulate
CLDN8 in colonic epithelial cells. Left panel: qPCR; right panel: western blot. c MiR-223 inhibitors upregulate CLDN8 in colonic epithelial cells. Left panel:
qPCR; right panel: western blot. d Upregulation of miR-223 in UC and CD. e Fluorescence in situ hybridization of miR-223 and immunostaining of
CLDN8 in human IBD tissues and normal tissues (magnification × 200). f MiR-223 regulates TEER. *P <0.05, **P <0.01, ***P <0.001 as compared with
the control
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upregulated in the colonic mucosa of TNBS-induced
colitis mice (Fig. 7b). However, treatment of these ani-
mals with anti-IL23P19 reduced the miR-233 by 56 %
(P <0.001, Fig. 7c).
By reducing miR-223 with the antagomir, we observed
a parallel increase of CLDN8 in the colitis model
(Fig. 7d). Collectively, these data suggest that miR-223
interacts with the IL23/Th17 pathway and the target
gene-CLDN8 in IBD (Fig. 7e).
Discussion
IL23 is a crucial factor in the manifestation of intestinal
inflammation in IBD. Through the expansion of a patho-
genic memory-activated T cell population, IL23 triggers an
inflammatory cascade leading to intestinal inflammation.
Using the TNBS-induced colitis animal model, we for the
first time have identified miR-223 as a critical component
of the IL23 inflammatory cascade in IBD. MiR-223 func-
tions as a pro-inflammatory microRNA and is tightly con-
trolled by IL23 in IBD. Pro-inflammatory miR-223 directly
targets Claudin-8 (CLDN8), a critical family member in
the maintenance of normal intestinal barrier property. Our
study characterizes this novel IL23/miR-223/CLDN8 path-
way in the development of IBD (Fig. 7e).
TNBS-induced colitis is a well-established animal
model to study mucosal inflammation for IBD pathogen-
esis and preclinical studies [26, 27]. In this study, we
have used three parameters to give a comprehensive
evaluation of the inflammation of colitis, including path-
ology score, MPO activity, and FITC permeability. The
C FITC D IHC staining of CLDN8





























































Fig. 6 Therapeutic treatment of miR-223 antagomirs in TNBS-induced colitis mice. a Recovery of body weight in mice with colitis by miR-223
antagomirs. Control: colitis mice treated with ethanol; TNBS + Anti-miR: colitis mice treated with antagomir223; TNBS + Anti-CTL: colitis mice
treated with an isotype control of antagomir223. ***P <0.001 for comparison between the TNBS + Anti-CTL group and the Ethanol Control group;
#P <0.05, ##P <0.01, ###P <0.001 for the statistical significance between the TNBS + Anti-miR group and the TNBS + anti-CTL group. b Representative
images of the colon (H&E staining). c Serum FITC-dextran was quantified as a measure of intestinal permeability. d-f Antagomir223 upregulates CLDN8
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pathology score is a rough estimation of inflammation
ranked by lab technicians. Although the therapeutic role
of anti-IL23P19 has been well documented [28, 29], we
found that the antibody treatment reduced the score in
a very modest functional significance (Fig. 1d). In con-
trast, MPO is an enzyme found predominantly in the
C Anti-IL23P19 downregulates miR-223 D Antagmir223 increases CLDN8
E The IL23/miR-223/ CLDN8 pathway
































































































B miR-223 in TNBS-induced IBDA miR-223
Fig. 7 Interaction among IL23, miR223 and CLDN8. a IL23 controls the expression of miR-223 in NCM460 and Caco-2 cells. NCM460 is a human
colon mucosal epithelial cell line. b miR-223 is upregulated in the colonic mucosa of mice with TNBS-induced colitis. c The anti-IL23P19 therapy
reduces the expression of miR-223. d Antagomir223 upregulates the RNA expression of CLDN8. e The proposed IL23/miR-223/CLDN8 pathway.
Activation of the IL23 cascade upregulates the pro-inflammatory miR-223. By targeting CLDN8, miR-223 impairs intestinal barrier, leading to the
development of IBD. M: Macrophage; DC: Dendritic cells. *P <0.05, **P <0.01, ***P <0.001 as compared with the control
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azurophilic granules of neutrophils as well as in mono-
cytes and macrophages. Measurement of MPO activity is
directly associated with neutrophil content, thus used as
a quantitative index of inflammation in colitis [30].
Using this assay, we found a more statistical significance
after the anti-IL23P19 treatment (Fig. 1f ). Additionally,
impaired epithelial barrier causes the increment in intes-
tinal permeability. Quantitation of FITC permeability
also gives a reliable estimation of colitis pathogenesis
(Fig. 1e). Together, we demonstrate that the anti-IL23P19
treatment significantly alleviated colitis pathogenesis as
previously reported [28, 29].
The intestinal epithelial barrier preserves the integrity
of the intestine. The colonic mucosal barrier consists of
a mucous layer and epithelial cells, which is the first
physical barrier in intestinal innate immunity. A healthy
barrier stops the invasion of pathogens and toxic sub-
stances, but remains tolerant to food antigens and nor-
mal microbiome [31–33]. Impaired epithelial barrier
function causes increased intestinal permeability, trigger-
ing compensatory immune reactions, and a chronic in-
flammatory response. Recent murine and human studies
have shown that defective barrier function is associated
with IBD. Patients with IBD and their healthy relatives
have increased intestinal permeability, suggesting that
barrier dysfunction is an important feature contributing
to inflammation in IBD [34, 35].
Claudins are a family of proteins that consists of more
than 27 members. They were regarded as essential for
maintenance of the intestinal barrier. Dysregulated clau-
dins might lead to injury of the intestinal epithelial bar-
rier. Some studies have found that dysregulated claudins
were involved in CD patients. For example, Zeissig et al.
reported that claudin-5 and CLDN8 were downregulated
in active CD patients, while claudin-2 was strongly upreg-
ulated. Other claudins such as claudin-1, 4, and 7 were
unchanged [36]. Using integrated microarray analysis,
Clark et al. found CLDN8 was highly downregulated in
both CD and UC tissues [37]. Other studies have found
that claudin-1, claudin-2, and claudin-4 expression were
elevated in IBD patients [38, 39]. However, the role of
claudins in the IL23 inflammatory cascade remains un-
defined. In this study, we show that CLDN8 was downreg-
ulated in both IBD patients and in mice with TNBS-
induced colitis under the control of miR-223. Decreasing
CLDN8 using siRNA reduced the TEER in Caco-2 cells.
Ectopic expression of CLDN8 enhanced the tight junction
of epithelial cells. These data suggest that CLDN8 might
play an important role in the injury of intestinal epithelial
barrier of IBD.
MiRNAs are thought to be involved in the pathogen-
esis of the inflammation in IBD. Using IL-10(−/−) mice
as an animal model of Th1-mediated inflammatory
bowel disease, Schaefer et al. showed that miR-223 was
one of the miRNAs that was dysregulated in colonic tis-
sues and PBLs of mice with mild intestinal pathology.
The 3’ untranslated region of the Roquin ubiquitin lig-
ase gene was a target for miR-223 [40]. Later, they also
found that 26 miRNAs, including miR-223, were altered
in colon biopsies of CD and UC patients [41]. Quite re-
cently, Polytarchou et al. also showed that miR-223 was
one of the 12 circulating microRNAs that differentiate
patients with UC from control subjects [42]. In this
study, we identified CLDN8 as a downstream target of
miR-223 in the IL23 pathway. Importantly, we demon-
strate that knockdown of miR-223 restores CLDN8
levels in mice with colitis and that it mitigates progres-
sion of colitis. Thus, miR-223 antagomir can ameliorate
progression of colitis. MiR-223 may enhance the muco-
sal healing by repairing the injuries of intestinal epithe-
lial barrier.
It should be emphasized that many other miRNAs, in
addition to miR-223, may also be involved in the IL-23/
Th17 pathway. For example, in this study we screened
miRNAs that have been reported to be upregulated in
IBD, including miR-223, miR-21, miR-155, miR-19a,
miR-101, miR-594, and miR-16. Among them, miR-223
is the most upregulated miRNA. Additionally, a single
miRNA may target tens to hundreds of distinct mRNAs,
and an individual mRNA may be directly regulated by
multiple miRNAs [43]. For example, Dorhoi et al. re-
ported in tuberculosis that miR-223 directly targets the
chemoattractants CXCL2, CCL3, and IL-6 in myeloid
cells [44] and miR-223 downregulated the expression of
STAT3 in sepsis [45]. Interestingly, by searching miR-
223 targets (http://mirtarbase.mbc.nctu.edu.tw), it seems
that some of the miR-223 targets are pro-inflammatory,
indicating that miR-223 may be an anti-inflammatory
microRNA. In our colitis model, however, we found that
miR-223 is a pro-inflammatory miRNA. Similar pro-
inflammatory role of miR-223 has been reported in other
models [46–49]. Thus, future studies are needed to ex-
plore the miRNA/target RNA interactome network in
the IL-23 pathway.
The approaches used to deliver drugs to animals with
colitis include intraperitoneal [11, 50, 51], tail vein [52],
or intracolonic administration [53]. By comparing intra-
peritoneal, caudal vein, and intracolonic delivery in our
pilot studies, we were surprised to find that intraperitoneal
delivery of anti-IL23P19 and antagomir223 was the most
effective way to treat mice with TNBS-induced colitis.
Theoretically, the intracolonic administration should be a
more direct and colon-specific approach. However, intrar-
ectal administration of TNBS during model establishment
may damage the intestinal mucosa and thus influence
drug absorption. Nonetheless, intracolonic administration
of antagomir223 also alleviated TNBS-induced colitis
(Additional file 6: Figure S4).
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The IL23/Th17 pathway plays an important role in
many autoimmune diseases including IBD [10]. Mono-
clonal antibodies targeting IL23p19 promote mucosal
healing in experimental colitis [11]. In preclinical trials,
Ustekinumab, a human monoclonal antibody against
IL23, was effective in treating CD patients [54, 55]. A
previous study demonstrates that IL–23 induces migra-
tion and invasion in thyroid cancer cells through the
miR–25/SOCS4 signaling pathway [56]. In this study, we
have made the novel observation that IL23 upregulates
miR-223. Correspondingly, a monoclonal antibody that
targets IL23 alleviates this process, leading to the down-
regulation of CLDN8. In experimental colitis, we found
that the therapy that target the IL23/miR-223 pathway
could decrease weight loss and improve histological ap-
pearance, histological score and MPO activity, and the
integrity of the intestinal epithelial barrier.
Conclusion
Our findings suggest a new mechanistic pathway in the
IL23 cascade in IBD. MiR-223 functions as a pro-
inflammatory molecule interacting with the IL23 path-
way. By targeting CLDN8, miR-223 directly bridges the
IL23 signal with intestinal barrier properties in IBD.
Thus, disrupting this IL23/miR-223/CLDN8 interaction
may provide novel therapeutic strategies for the manage-
ment of IBD.
Methods
Human IBD colon tissues
Colon biopsies were obtained from IBD patients and
healthy volunteers during endoscopy at the First Affili-
ated Hospital, Sun Yat-sen University. Informed written
consent was given by all the participants. The study
protocol was approved by the Human Ethics Committee
of the First Affiliated Hospital, Sun Yat-Sen University,
and experimental methods comply with the Helsinki
Declaration.
Cell lines and culture conditions
SW480 (human colon adenocarcinoma), Caco-2 (human
epithelial colorectal adenocarcinoma), and 293T (human
embryonic kidney) cell lines were purchased from
American Tissue Culture Collection (ATCC, VA, USA),
and NCM460 (a human colon mucosal epithelial cell line)
was purchased from Jennio Biotechnology (Guangzhou,
China). All cells were cultured in 1640 medium supple-
mented with 10 % fetal bovine serum, penicillin, and
streptomycin in a 5 % CO2 incubator.
RNA preparation, Q-PCR for miRNA, and mRNA
abundance
Total RNA was extracted from colon biopsies or cell lines
using Trizol Reagent (Invitrogen, Carlsbad, CA, USA).
The Transcriptor First Stand cDNA Synthesis Kit (Roche)
and the Fast Start Universal SYBR Green Master (Roche)
were used to confirm the miRNA and mRNA expression
changes. The expression of each target miRNA and
mRNA was calculated, respectively, relative to U6 or β-
Actin. A comparative threshold cycle method was used
to compare each condition with controls.
Western blotting analysis
Total proteins were added to RIPA buffer (CST, USA)
and boiled at 95 °C for 5 min. The proteins were then
routinely processed for western blotting as described
previously [57]. Briefly, the proteins were separated on
10 % SDS polyacrylamide gels and blotted onto nitrocel-
lulose membranes which were incubated in TBST-milk,
followed by primary antibodies (4 °C, overnight) for
CLDN8 IgG antibody (2 μg/mL, Gene Tex) (1:1,000 dilu-
tion) and GAPDH antibody (1:1,000, CST). Blots were
then washed with TBST three times (10 min each) and
subsequently incubated (1 h) with anti-rabbit IgG HRP-
linked antibody (1:3,000, CST). Each western blot was
repeated at least three times.
Immunohistochemical staining (IHC)
The paraffin sections were deparaffinized in xylene and
hydrated through a graded series of alcohol to tap water.
Antigen retrieval was performed by microwave irradi-
ation in citrate buffer for 20 min and cooled to room
temperature. The sections were incubated with 3 %
H2O2 in distilled water for 15 min to quench the en-
dogenous peroxidase activity. After being rinsed three
times with PBS, the sections were incubated with Rabbit
polyclonal to CLDN8 IgG antibody (2 μg/mL, Gene Tex)
(1:500 dilution) overnight at 4 °C, and then washed in
PBS; the sections were incubated with the secondary anti-
body (Dako) for 30 min at room temperature. Finally, the
sections were counter stained with hematoxylin.
Fluorescence in situ hybridization (FISH)
In situ hybridization for miR-223 and CLDN8 was per-
formed on paraffin sections of biopsies. The paraffin sec-
tions were deparaffinized in xylene and hydrated through
a graded series of alcohol to tap water. Proteinase K diges-
tion was used to treat fixed tissues at 37 °C for 5 min.
After digestion, slides were immersed in RNase-free water
for 3 min and then air dried. Hybridization was carried
out overnight at 55 °C using hybridization buffer sup-
plemented with denatured FITC-labeled Locked Nucleic
Acid (LNA) probes (1:200, Exiqon) directed against
miR-223. Scrambled LNA probes were used as a nega-
tive control. Simultaneous immunostainings were con-
ducted using a rabbit polyclonal to CLDN8 IgG
antibody (2 μg/mL, Gene Tex) (1:500 dilution), followed
by cy3-conjugated anti-rabbit secondary antibodies
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(1:400 dilution) for 30 min at room temperature. After
washing, the sections were counterstained with 4’, 6-
diamidino-2-phenylindole (DAPI) for 1 min. Images were
captured with a Zeiss LSM710 confocal microscope
(Zeiss, Oberkochen, Germany).
CLDN8 3’-UTR construct and luciferase report assay
The 3’-UTR of CLDN8 mRNA bearing miRNA binding
sites (corresponding to 905–2147 nucleotides of RefSeq
NM_199328.2) was cloned into the XhoI and NotI sites
downstream of the Renilla luciferase reporter vector,
pmiR-RB-REPORT (RiboBio, Guangzhou, China), ac-
cording to the manufacturer’s instructions. The miR-RB-
REPORT-mutated vector was generated corresponding
to the predicted binding sites on the CLDN8 3’-UTR for
miR-223. For the miRNA binding site, eight nucleotides
in the 5’seeding region were substituted. Each pMIR
construct (100 nM), along with the renilla luciferase
control plasmid, phRL-CMV (Promega; 200 ng/well),
was transfected into 293T cells in 24-well plates using
Lipofectamine 2000 (Invitrogen) according to the manu-
facturer’s guidelines. Cells were harvested 48 h after
transfection. Firefly and renilla luciferase activities were
measured using the Dual Luciferase Reporter Assay Sys-
tem (Promega) according to the manufacturer’s instruc-
tions. Experiments were performed in triplicate.
Knockdown of CLDN8 by siRNA and ectopic expression of
CLDN8
We used predesigned siRNA for CLDN8 as follows: 5’
GGGACAAUGAGAAGGUGAA dTdT 3’, 3’dTdT CCC
UGUUACUCUUCCACUU 5’. Transient transfection of
siRNA into Caco-2 and NCM460 cells was performed
using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. The ectopic expression of
CLDN8 with CLDN8 plasmid (Vigenebio, CH855544)
into the above cells was performed using a similar
procedure.
Transfection of miRNA mimics and inhibitors
The micrONTM miRNA mimics and inhibitors to
miR-223 and the negative control #22 were obtained
from RiboBio (Guangzhou, China). Caco-2, SW480, and
NCM460 cells in 1640 medium containing 10 % fetal
bovine serum were placed into 12-well plates at 50 %
confluence at 37 °C in a 5 % CO2 incubator. After 24 h,
the culture media was replaced with 1640 medium
(without serum and antibiotics). MiRNA mimics, inhibi-
tors, and the negative control were transiently transfected
into the cells using Lipofetamine 2000 (Invitrogen, CA,
USA) following the manufacturer’s instructions. The
transfected cells were incubated at 37 °C in a 5 % CO2 in-
cubator for 48 h for further study.
Measurement of transepithelial electrical resistance (TEER)
TEER, a reliable indication of the tightness of junctions
between colonic cells, was measured as described previ-
ously [58]. In brief, Caco-2 cells were seeded at a density
of 2 × 105cells/cm2 on the top of transwell polycarbonate
filters (pore size, 3 μm; diameter, 24 mm; growth area,
4.5 cm2) from Costar (Millipore). Caco-2 monolayers
were used 21 days after seeding. TEERs of the mono-
layers were measured using Millicell ERS-2 (Millipore,
Germany).
Cell treatment with Anti-IL23P19
Colonic epithelial cells were plated at density of 2 × 105
cells per well in 6-well plates. Cells were treated for 0,
12, 24, 36, 48, 60, and 72 h with IL23 (20 ng/mL) with
or without anti-IL23P19 neutralizating antibody (anti-
IL23P19) (6 μg/mL) or its isotype control. We found
that the expression of CLDN8 decreased with time but
became stabilized between 60 and 72 h (Additional
file 7: Figure S5). Thus, a 72 h exposure was chosen
for the study.
TNBS-induced colitis model
Trinitrobenzene sulfonic acid (TNBS)-induced colitis are
well-established models to study mucosal inflammation.
The colitis model was established in the IBD center, First
Affiliated Hospital, Sun Yat-sen University, following the
procedure as previously reported [59]. Briefly, pathogen-
free male BALB/c mice (6–8 weeks) were obtained from
Slack Jingda Experimental Animal LTD of Hunan prov-
ince (Hunan, China) and maintained under specific
pathogenic-free conditions in the animal facilities of Sun
Yat-Sen University. Animals were pre-sensitized with
1 % trinitrobenzene sulfonic acid (TNBS, Sigma, St
Louis, MO, USA) at day 1, and received 2.5 % TNBS
(mixing 1 volume of 5 % (w/v) TNBS with 1 volume of
absolute ethanol) (2.5 mg/20 g, about 100 μL) intrarec-
tally at day 8 [59].
In our pilot studies, we tested different doses of anti-
IL23P19 and found that intraperitoneal injection of anti-
IL23P19 at the dose of 0.5 mg/kg yielded the best thera-
peutic effect. This dose was thus used for the following
study. Experimental animals were divided into three
groups (10 mice per group). In Group 1, animals re-
ceived TNBS dissolved in ethanol. Twenty-four hours
after administration of TNBS, animals were treated with
a neutralizing anti-mouse IL23 antibody (anti-IL23P19,
Clone: G23-8; eBioscience) via intraperitoneal injection
(0.5 mg/kg) for three consecutive days (TNBS + P19). In
Group 2, after receiving TNBS, animals were treated
with the isotype control (TNBS + ISO). In Group 3, ani-
mals received 100 μL of 50 % ethanol alone as the nega-
tive control (Control).
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Histological assessment of colitis
The colonic tissues of TNBS-colitis were removed, fixed
in 10 % buffered formalin, embedded in paraffin, and tis-
sue sections were stained with hematoxylin and eosin.
The histology were scored blindly by lab technicians
from Department of Pathology in the IBD-MDT center
using previously described criteria [60]: 0, no signs of in-
flammation; 1, very low level; 2, low level of leukocyte
infiltration; 3, high level of leukocyte infiltration, high
vascular density, thickening of the colon wall; and 4,
transmural infiltration, loss of globet cells, high vascular
density, thickening of the colon wall.
Myeloperoxidase (MPO) activity
The MPO activity assay, a biochemical assay for acute
intestinal inflammation, was performed within 1 week of
the collection of the colonic tissues according to the in-
structions of the MPO assay kit (Jiancheng BioEngineer-
ing, Nanjing, China). The absorbance was measured at
460 nm using a Life Science UV Spectrophotometer DU
530 (Beckman Coulter, USA). The MPO activity was
expressed in units per gram of tissue, and 1 U corre-
sponded to the activity required to degrade 1 mmol of
hydrogen peroxide per minute at 25 °C.
FITC-labeled dextran intestinal permeability assay
Intestinal permeability was examined on day 7 using the
FITC-labeled dextran method, as previously described
[61]. Briefly, mice were gavaged with 60 mg/100 g of
FITC dextran (MW 4,000 at 80 mg/mL, Sigma) 4 h be-
fore sacrifice. Cardiac puncture was performed, blood
was collected, and FITC concentrations were measured
in plasma (Fluorimeter Pharos FX; BioRad, Hercules,
CA, USA). A standard curve was obtained by dilut-
ing serial concentrations of FITC-Dextran in mouse
serum. Serum analysis of FITC concentration was imme-
diately performed in triplicate by using Spectra Max M5
(485/520 nm).
Therapy of TNBS-induced colitis by miR-223 antagomir
Chemically modified miRNA antagomirs (Ambion,
Austin, TX, USA) complementary to the mature miR-223
sequences were used to knock down miR-223 expression
in vivo. The miR-223 antagomir was a 22-mer with the se-
quence 5’- UGUCAGUUUGUCAAAUACCCCA-3’, while
the negative control sequence was a 21-mer with the se-
quence 5’-CAGTACTTTTGTGTAGTACAA-3’. All sub-
stances were dissolved at 3 mg/mL in RNase-free sterile
PBS. In a pilot study, we compared the effect of different
doses of antagomir-223 in our model (Additional file 5:
Figure S3A). Based on these data, intraperitoneal injection
of 7.5 mg/kg antagomir-223 was used for the following
experiment.
The animals were divided into three groups. Two
groups (10 mice for one group) were administrated with
TNBS dissolved in ethanol, another group with ethanol
alone. The two TNBS group were administrated with
antagomir (7.5 mg/kg, intraperitoneal injection) and
antagomir-control separately for three consecutive days
24 h after administration of TNBS. The mice were ob-
served from day 1 to day 8. Body weights were moni-
tored before the induction of colitis and daily thereafter.
At the end of the experiment, the mice were sacrificed
by cervical dislocation under anesthesia.
Statistical analyses
Experimental results are expressed as mean ± SD. Statis-
tical analyses for Q-PCR were performed with the un-
paired, two-tailed Student’s t tests and one-way ANOVA
for comparing all pairs of groups (SPSS 16.0). P <0.05
was considered significant.
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Additional file 1: Table S1. Genes that showed greater than four-fold
upregulation in IBD. (XLSX 28 kb)
Additional file 2: Table S2. Genes that showed greater than four-fold
downregulation in IBD. (XLSX 14 kb)
Additional file 3: Figure S1. Identification of CLDN8 as a novel target
controlled by the IL23 pathway in IBD. A Heatmap of IBD-associated
mRNAs. Lanes 4A-6A:CD tissues; lanes 4B-6B: normal colons. B Western
blot of CLDN8 in colonic inflamed mucosa of IBD patients. C Western blot
of CLDN8 in colonic inflamed mucosa of colitis mice. D Anti-IL23P19 restored
CLDN8 by western blot. (EPS 2313 kb)
Additional file 4: Figure S2. Abundance of miR-223 in the mimic- and
inhibitor-treated cells. A MiR-223 mimics upregulate miR-223 in colonic
epithelial cells by qPCR. B MiR-223 inhibitors downregulate miR-223 in
colonic epithelial cells by qPCR. C MiR-223-positive cells in colonic mucosa
of IBD patients by FISH. *P <0.05, **P <0.01, ***P <0.001. (EPS 1921 kb)
Additional file 5: Figure S3. Therapeutic treatment of miR-223 antagomir
in mice with TNBS-induced colitis. A Dose-dependent study of miR-223
antagomir. B Representative images of the colon in treated mice with colitis.
C Antagomir223 therapy reduces the histological score. D Effects on MPO
activity measurement by antagomir223. E MiR-223 antagomirs downregulate
miR-223. *P <0.05, **P <0.01, ***P <0.001. (EPS 4652 kb)
Additional file 6: Figure S4. MiR-223 antagomirs therapy by direct
intracolonic delivery. A Recovery of body weight in mice with colitis by
miR-223 antagomirs. Control: colitis mice treated with ethanol; TNBS +
Anti-miR: colitis mice treated with antagomir223; TNBS + Anti-CTL: colitis
mice treated with an isotype control of antagomir223. B MiR-223 antagomirs
therapy reduces the histological score. C Serum FITC-dextran was quantified
as a measure of intestinal permeability. D Effects on MPO activity by miR-223
antagomirs. E MiR-223 antagomirs upregulate CLDN8 as quantitated by
qPCR. F MiR-223 antagomirs upregulate CLDN8 as quantitated by western
blot. G MiR-223 antagomirs downregulate miR-223. *P <0.05, **P <0.01,
***P <0.001. (EPS 5350 kb)
Additional file 7: Figure S5. IL23 reduced the expression of CLDN8 in
a time-dependent manner in NCM460 and Caco-2 cells. (EPS 758 kb)
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